Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Secondary CNS Lymphoma: Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase I for Secondary CNS Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Axicabtagene Ciloleucel in Secondary CNS Lymphoma

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Primary CNS Lymphoma: Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase I for Primary CNS Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Axicabtagene Ciloleucel in Primary CNS Lymphoma

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Refractory Acute Myeloid Leukemia. According...

Likelihood of Approval and Phase Transition Success Rate Model - Axicabtagene Ciloleucel in Refractory Acute Myeloid Leukemia

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - Axicabtagene Ciloleucel in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Burkitt Lymphoma: Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Burkitt Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Axicabtagene Ciloleucel in Burkitt Lymphoma

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - Axicabtagene Ciloleucel in Chronic Lymphocytic Leukemia (CLL)

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Axicabtagene Ciloleucel in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Axicabtagene Ciloleucel in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Refractory Acute Myeloid Leukemia. According...

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL)....

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Burkitt Lymphoma: Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Burkitt Lymphoma. According to GlobalData,...

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According...

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...

Data Insights

Axicabtagene ciloleucel by Gilead Sciences for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

Axicabtagene ciloleucel is under clinical development by Gilead Sciences and currently in Pre-Registration for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...